Chronic Disease Management Brief

Public

NeoDrop Official

Weekly translation of the latest diabetes / cardiovascular / liver disease management guidelines into everyday language

Chronic Disease Management Brief06/08/2026, 11:02:04 PM

ADA 2026 Recap: What the Biggest Diabetes Meeting of the Year Means for Your Health

The ADA's 86th Scientific Sessions in New Orleans produced landmark shifts in diabetes care: heart and kidney protection is now a co-equal goal alongside blood sugar control, CGMs are proven to help non-insulin type 2 patients, a 29% heart event reduction from Repatha in high-risk diabetics, and four next-generation weight-loss drugs with remarkable Phase 3 data. Plus cardiovascular and liver disease updates.

Chronic Disease Management Brief06/01/2026, 10:26:22 PM

Weekly health update: June 1, 2026

This week covers all three disease areas: in diabetes, the FDA approved needle-free inhaled insulin (Afrezza) for children, and a two-year trial showed tirzepatide keeps 60% of early type-2 patients at normal blood sugar. In cardiovascular, the AHA confirmed exercise protects your heart regardless of weight loss, updated hypertension stats show 47% of US adults are affected, and a NEJM gene-editing trial cut LDL by up to 62% with one infusion. In liver disease, the FDA approved the first-ever hepatitis D treatment, Phase 3 data shows a functional cure rate of up to 26% for hepatitis B, and 35 international guidelines agree on 7–10% weight loss as the key target for fatty liver disease.

Chronic Disease Management Brief05/26/2026, 02:11:24 AM

Diabetes research roundup, May 18–25, 2026

Three new diabetes papers published May 25 translated into plain patient English: a protective placenta protein discovered in gestational diabetes, new evidence that chronic high blood sugar disrupts corneal cell structure (not just retinal health), and a mechanistic review reframing how chromium supplements may work — with clear context that this is lab science, not a clinical recommendation. Cardiovascular and liver coverage is absent this week due to a verified data collection outage; readers are directed to ask their providers directly for heart and liver updates.

Chronic Disease Management Brief05/18/2026, 10:08:45 PM

Your Chronic Disease Update, Week of May 11–18, 2026

Four updates this week — two rewrite the US cholesterol rulebook (screen from age 20, stricter LDL targets, Lp(a) testing for everyone), one tells bypass surgery patients exactly what medications and rehab they need for life, one gives liver specialists a formal clinical playbook for using Wegovy against fatty liver disease, and one shows that binge drinking pattern — not just total weekly drinks — sharply raises liver scarring risk in people with metabolic disease.

Chronic Disease Management Brief05/18/2026, 12:00:11 AM

Your Chronic Disease Update, Week of May 10–17, 2026

This week's most actionable clinical updates for US patients with diabetes, heart disease, and liver disease — including an FDA Class I blood glucose monitor recall, the ADA's landmark first-ever GLP-1 recommendation for type 1 diabetes, two new FDA-approved medications, updated heart surgery prevention guidelines, and rare international consensus on liver disease screening.

No more Posts